Your browser doesn't support javascript.
loading
Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño, Anxo; Cenigaonandia-Campillo, Aiora; García-Bautista, Ana; Mateos-Gómez, Pedro A; Schlaepfer, Marina I; Del Puerto-Nevado, Laura; Aguilera, Oscar; García-García, Laura; Galeano, Carlos; de Miguel, Irene; Serrano-López, Juana; Baños, Natalia; Fernández-Aceñero, María Jesús; Lacal, Juan Carlos; Medico, Enzo; García-Foncillas, Jesús; Cebrián, Arancha.
Afiliação
  • Rio-Vilariño A; Translational Oncology Division, Oncohealth Institute, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Fundación Jiménez University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • Cenigaonandia-Campillo A; Translational Oncology Division, Oncohealth Institute, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Fundación Jiménez University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • García-Bautista A; Translational Oncology Division, Oncohealth Institute, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Fundación Jiménez University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • Mateos-Gómez PA; Biochemistry and Molecular Biology Unit, Department of System Biology, School of Medicine and Health Sciences, University of Alcalá. Alcalá de Henares, Madrid, Spain.
  • Schlaepfer MI; Translational Oncology Division, Oncohealth Institute, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Fundación Jiménez University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • Del Puerto-Nevado L; Translational Oncology Division, Oncohealth Institute, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Fundación Jiménez University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • Aguilera O; Translational Oncology Division, Oncohealth Institute, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Fundación Jiménez University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • García-García L; Translational Oncology Division, Oncohealth Institute, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Fundación Jiménez University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • Galeano C; Pathology Department, IIS-Fundación Jiménez Diaz-UAM, Madrid, Spain.
  • de Miguel I; Biochemistry and Molecular Biology Unit, Department of System Biology, School of Medicine and Health Sciences, University of Alcalá. Alcalá de Henares, Madrid, Spain.
  • Serrano-López J; Experimental Hematology Lab, IIS-Fundación Jimenez Díaz, UAM, Madrid, Spain.
  • Baños N; Preclinical program START Madrid-FJD, Hospital Fundación Jiménez Díaz-UAM, Madrid, Spain.
  • Fernández-Aceñero MJ; Department of Pathology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
  • Lacal JC; Instituto de Investigaciones Biomédicas, CSIC/UAM, Madrid, Spain.
  • Medico E; Instituto de Investigación Sanitaria Hospital La Paz, IDIPAZ, Madrid, Spain.
  • García-Foncillas J; Department of Oncology, Università degli Studi di Torino, Candiolo (TO), Italy.
  • Cebrián A; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.
Br J Cancer ; 130(8): 1414, 2024 May.
Article em En | MEDLINE | ID: mdl-38575733
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Br J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Br J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha